Muhammadyusuf Shkuratovich Abdykadyrov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Muhammadyusuf Shkuratovich Abdykadyrov has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Furkat Abdulakhatovich Yusupov
Osh State University
26 shared publications - T. F. Yusupova
Osh State University
7 shared publications - Ilkhom T. Murkamilov
Kyrgyz State Medical Academy named after I.K. Akhunbaev
5 shared publications - Akmal Akbarovich Yuldashev
Osh State University
4 shared publications - Kubanich Avenovich Aitbaev
Kyrgyz State Medical Academy named after I.K. Akhunbaev
4 shared publications - Z. F. Yusupova
Osh State University
4 shared publications
Latest Publications
- 20 October 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (9) , 15-21
Highlands as a natural neuroprotection laboratory: hypoxia and neurodegenerative processes
High altitude hypobaric hypoxia presents a unique stressor to the central nervous system, exerting a profound yet contradictory effect on the dopaminergic system. On one hand, uncontrolled hypoxia triggers pathological cascades characterized by a significant neurotoxic release of dopamine, increased oxidative stress, and the initiation of neurodegenerative processes akin to those observed in Parkinson’s and Alzheimer’s diseases. On the other hand, controlled moderate hypoxia, referred to as hypoxic preconditioning, along with the genetic adaptations found in highland natives, stimulates powerful endogenous neuroprotective mechanisms. This review consolidates data on molecular (e.g., HIF-1α, Wnt, and brain-derived neurotrophic factor) and biochemical (e.g., tyrosine hydroxylase and monoamine oxidase) responses to hypoxia, aiming to resolve this paradox. Special emphasis is placed on evolutionary selection driven by genes associated with the HIF pathway (e.g., EPAS1 and EGLN1), which may «tune» physiological responses to transform chronic hypoxic stress into a state of consistent neuroprotection. Understanding the transition from pathological risk to adaptive resistance opens new avenues for the development of hypoxic therapy in treating dopaminergic neurodegenerative diseases. The highlands, typically defined as altitudes exceeding 2.500 meters above sea level, serve as a natural laboratory for investigating the effects of chronic hypobaric hypoxia and the mechanisms of human adaptation.
- 20 October 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (9) , 15-21
Highlands as a natural neuroprotection laboratory: hypoxia and neurodegenerative processes
High altitude hypobaric hypoxia presents a unique stressor to the central nervous system, exerting a profound yet contradictory effect on the dopaminergic system. On one hand, uncontrolled hypoxia triggers pathological cascades characterized by a significant neurotoxic release of dopamine, increased oxidative stress, and the initiation of neurodegenerative processes akin to those observed in Parkinson’s and Alzheimer’s diseases. On the other hand, controlled moderate hypoxia, referred to as hypoxic preconditioning, along with the genetic adaptations found in highland natives, stimulates powerful endogenous neuroprotective mechanisms. This review consolidates data on molecular (e.g., HIF-1α, Wnt, and brain-derived neurotrophic factor) and biochemical (e.g., tyrosine hydroxylase and monoamine oxidase) responses to hypoxia, aiming to resolve this paradox. Special emphasis is placed on evolutionary selection driven by genes associated with the HIF pathway (e.g., EPAS1 and EGLN1), which may «tune» physiological responses to transform chronic hypoxic stress into a state of consistent neuroprotection. Understanding the transition from pathological risk to adaptive resistance opens new avenues for the development of hypoxic therapy in treating dopaminergic neurodegenerative diseases. The highlands, typically defined as altitudes exceeding 2.500 meters above sea level, serve as a natural laboratory for investigating the effects of chronic hypobaric hypoxia and the mechanisms of human adaptation.
- 16 October 2026
- Published by Media Sphere Publishing Group in Burdenko's Journal of Neurosurgery
- Vol. 90 (5) , 113-119
Sex differences in neuroplasticity and functional recovery after neurosurgical interventions
Objective. To analyze modern data on the influence of biological sex and gender factors on mechanisms of neuroplasticity and functional recovery after neurosurgical interventions. Material and methods. We reviewed the databases (PubMed, Scopus, Russian Science Citation Index (RSCI) and Google Scholar) over the past 10 years. The review covers clinical trials, prospective and retrospective cohort studies and animal models of traumatic brain injury, surgery for brain cancer, vascular accidents and spinal cord injury. The main parameters were diffusion tensor imaging data, functional MRI, hormonal profile and standardized clinical scales including the modified Rankin scale, Barthel index, ASIA and FIM scales. Results. Female brain has better interhemispheric connectivity that provides adaptive advantage in focal lesions of dominant hemisphere. Male brain is optimized for intrahemispheric signaling promoting faster motor coordination. Estrogens and progesterone have neuroprotective effect through modulation of inflammatory response and support of myelination, but this effect depends on age and phase of reproductive cycle. In clinical practice, women often demonstrate lower rates of functional independence at discharge after stroke due to comorbidity and social factors, despite equal or superior potential for neurological recovery compared to men. Conclusion. Biological sex is a critical determinant of neurosurgical outcomes. Discrepancy between biological recovery potential (higher in women) and actual functional outcomes (often better in men) highlights the need to develop personalized, gender-specific rehabilitation protocols taking into account specifics of connectome and hormonal backgrounds.
- 16 October 2026
- Published by Media Sphere Publishing Group in Burdenko's Journal of Neurosurgery
- Vol. 90 (5) , 113-119
Sex differences in neuroplasticity and functional recovery after neurosurgical interventions
Objective. To analyze modern data on the influence of biological sex and gender factors on mechanisms of neuroplasticity and functional recovery after neurosurgical interventions. Material and methods. We reviewed the databases (PubMed, Scopus, Russian Science Citation Index (RSCI) and Google Scholar) over the past 10 years. The review covers clinical trials, prospective and retrospective cohort studies and animal models of traumatic brain injury, surgery for brain cancer, vascular accidents and spinal cord injury. The main parameters were diffusion tensor imaging data, functional MRI, hormonal profile and standardized clinical scales including the modified Rankin scale, Barthel index, ASIA and FIM scales. Results. Female brain has better interhemispheric connectivity that provides adaptive advantage in focal lesions of dominant hemisphere. Male brain is optimized for intrahemispheric signaling promoting faster motor coordination. Estrogens and progesterone have neuroprotective effect through modulation of inflammatory response and support of myelination, but this effect depends on age and phase of reproductive cycle. In clinical practice, women often demonstrate lower rates of functional independence at discharge after stroke due to comorbidity and social factors, despite equal or superior potential for neurological recovery compared to men. Conclusion. Biological sex is a critical determinant of neurosurgical outcomes. Discrepancy between biological recovery potential (higher in women) and actual functional outcomes (often better in men) highlights the need to develop personalized, gender-specific rehabilitation protocols taking into account specifics of connectome and hormonal backgrounds.
- 23 September 2026
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 24 (3)
Pain and skin: an interdisciplinary perspective on safe analgesic methods
Transdermal analgesia is a non-invasive method of drug delivery through the skin for the treatment of various pain syndromes. This review examines fundamental principles of transdermal drug delivery, classification of analgesics (opioid and non-opioid), their application, and effectiveness in different clinical scenarios, including postoperative pain management, treatment of chronic and acute pain, cancers and neuropathic pain. The review highlights the advantages of transdermal analgesia, such as prolonged and controlled drug release, avoidance of first-pass metabolism in liver, improved patient adherence to treatment, and lower risk of systemic side effects. Limitations are also discussed, including constraints related to physicochemical properties of drugs, delayed onset of action for certain medications, and potential for local skin reactions. Additionally, the review explores recent advancements and future prospects in transdermal analgesic systems, including active delivery technologies (iontophoresis, ultrasound), microneedle technologies, and “smart” patches that may enhance efficacy and expand the range of transdermal analgesic applications. Clinical significance of transdermal analgesia lies in its ability to provide an effective alternative to traditional analgesic methods, particularly for chronic pain and in patients with difficult oral or injectable drug intake.
- 23 September 2026
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 24 (3)
Pain and skin: an interdisciplinary perspective on safe analgesic methods
Transdermal analgesia is a non-invasive method of drug delivery through the skin for the treatment of various pain syndromes. This review examines fundamental principles of transdermal drug delivery, classification of analgesics (opioid and non-opioid), their application, and effectiveness in different clinical scenarios, including postoperative pain management, treatment of chronic and acute pain, cancers and neuropathic pain. The review highlights the advantages of transdermal analgesia, such as prolonged and controlled drug release, avoidance of first-pass metabolism in liver, improved patient adherence to treatment, and lower risk of systemic side effects. Limitations are also discussed, including constraints related to physicochemical properties of drugs, delayed onset of action for certain medications, and potential for local skin reactions. Additionally, the review explores recent advancements and future prospects in transdermal analgesic systems, including active delivery technologies (iontophoresis, ultrasound), microneedle technologies, and “smart” patches that may enhance efficacy and expand the range of transdermal analgesic applications. Clinical significance of transdermal analgesia lies in its ability to provide an effective alternative to traditional analgesic methods, particularly for chronic pain and in patients with difficult oral or injectable drug intake.
- 1 September 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (8)
Clinical and functional characteristics of Parkinson’s disease in patients with chronic kidney disease
Objective. To evaluate the clinical and functional characteristics of Parkinson’s disease in patients with and without concomitant chronic kidney disease (CKD) and to assess the impact of renal dysfunction on motor, cognitive, and non-motor symptoms. Material and methods. A cross-sectional study was conducted involving 62 patients diagnosed with idiopathic Parkinson’s disease at stages I—III. The test group comprised 31 patients with an estimated glomerular filtration rate (eGFR) of 30—59 mL/min/1.73 m², while the control group comprised 31 patients with an eGFR of 60 mL/min/1.73 m² or higher. Various assessments were performed, including the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), Hoehn and Yahr Scale, Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), and evaluations for depression, anxiety, and orthostatic dysfunction. Results. Demographic factors such as age, sex, and duration of Parkinson’s disease were similar between the groups; however, patients with CKD had a higher Hoehn and Yahr score (2.5 vs. 2.0; p<0.05). Although the levodopa equivalent dose was greater in this cohort, the difference was not statistically significant. With an equal duration of the disease, motor impairments were more severe in the CKD group, with MDS-UPDRS III scores of 42.8±8.5 compared to 34.6±7.2 in the control group (p<0.001). In patients with CKD, axial symptoms, including gait disturbances, postural instability, and bradykinesia, were more prominent, while resting tremor was less evident. Cognitive function assessments revealed a decline in performance in patients with CKD: MMSE scores averaged 24.8±2.1, compared with 26.5±1.8 in the control group (p<0.05), and MoCA scores averaged 20.6±3.4, compared with 25.4±2.2 (p<0.001), respectively. Among the CKD patients, 83.8% exhibited mild cognitive impairment (MoCA< 26), contrasting with 38.7% in the control group. Specifically, executive, visual-spatial, attention, and memory functions were significantly impacted. A positive correlation was found between eGFR and total MoCA scores (rS=0.48; p=0.005). Furthermore, non-motor manifestations were more common in the CKD group, with rates of depression at 64.5% vs. 38.7%, anxiety at 58.1% vs. 32.2%, constipation at 74.2% vs. 51.6%, daytime sleepiness at 54.8% vs. 25.8%, and orthostatic hypotension at 38.7% vs. 19.4% (p<0.05). Conclusions. The presence of CKD is associated with a more severe motor and cognitive phenotype in Parkinson’s disease, predominantly characterized by axial dysfunction and diminished executive functions. These findings highlight the importance of assessing renal function when evaluating the progression of Parkinson’s disease.
- 1 September 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (8)
Clinical and functional characteristics of Parkinson’s disease in patients with chronic kidney disease
Objective. To evaluate the clinical and functional characteristics of Parkinson’s disease in patients with and without concomitant chronic kidney disease (CKD) and to assess the impact of renal dysfunction on motor, cognitive, and non-motor symptoms. Material and methods. A cross-sectional study was conducted involving 62 patients diagnosed with idiopathic Parkinson’s disease at stages I—III. The test group comprised 31 patients with an estimated glomerular filtration rate (eGFR) of 30—59 mL/min/1.73 m², while the control group comprised 31 patients with an eGFR of 60 mL/min/1.73 m² or higher. Various assessments were performed, including the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), Hoehn and Yahr Scale, Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), and evaluations for depression, anxiety, and orthostatic dysfunction. Results. Demographic factors such as age, sex, and duration of Parkinson’s disease were similar between the groups; however, patients with CKD had a higher Hoehn and Yahr score (2.5 vs. 2.0; p<0.05). Although the levodopa equivalent dose was greater in this cohort, the difference was not statistically significant. With an equal duration of the disease, motor impairments were more severe in the CKD group, with MDS-UPDRS III scores of 42.8±8.5 compared to 34.6±7.2 in the control group (p<0.001). In patients with CKD, axial symptoms, including gait disturbances, postural instability, and bradykinesia, were more prominent, while resting tremor was less evident. Cognitive function assessments revealed a decline in performance in patients with CKD: MMSE scores averaged 24.8±2.1, compared with 26.5±1.8 in the control group (p<0.05), and MoCA scores averaged 20.6±3.4, compared with 25.4±2.2 (p<0.001), respectively. Among the CKD patients, 83.8% exhibited mild cognitive impairment (MoCA< 26), contrasting with 38.7% in the control group. Specifically, executive, visual-spatial, attention, and memory functions were significantly impacted. A positive correlation was found between eGFR and total MoCA scores (rS=0.48; p=0.005). Furthermore, non-motor manifestations were more common in the CKD group, with rates of depression at 64.5% vs. 38.7%, anxiety at 58.1% vs. 32.2%, constipation at 74.2% vs. 51.6%, daytime sleepiness at 54.8% vs. 25.8%, and orthostatic hypotension at 38.7% vs. 19.4% (p<0.05). Conclusions. The presence of CKD is associated with a more severe motor and cognitive phenotype in Parkinson’s disease, predominantly characterized by axial dysfunction and diminished executive functions. These findings highlight the importance of assessing renal function when evaluating the progression of Parkinson’s disease.
- 12 August 2026
- Published by Media Sphere Publishing Group in Stomatologiya
- Vol. 105 (4) , 34-39
Clinical characteristics of pain syndromes in dental practice among patients with chronic kidney disease
The analysis of the etiology, pathogenesis and clinical features of the appearance of pain syndrome in the maxillofacial region in patients with chronic kidney disease is presented. The mechanisms of the effect of uremic intoxication on the oral mucosa and the peripheral nervous system are considered. Specific conditions such as uremic stomatitis, trigeminal neuropathy, and burning mouth syndrome have been identified. Special attention is paid to the manifestations of bone mineral disorders (CKD-MBD), including renal osteodystrophy of the jaws. The approach to pharmacological pain relief is systematized: a strict ban on the use of nonsteroidal anti-inflammatory drugs (NSAIDs) is justified and algorithms for the safe dosing of analgesics and adjuvants (gabapentinoids) are proposed, taking into account the reduced glomerular filtration rate and dialysis clearance. Clinical recommendations on dental treatment tactics, including hemostasis measures and timing of hemodialysis sessions to minimize the risks of complications, are also formulated.
- 12 August 2026
- Published by Media Sphere Publishing Group in Stomatologiya
- Vol. 105 (4) , 34-39
Clinical characteristics of pain syndromes in dental practice among patients with chronic kidney disease
The analysis of the etiology, pathogenesis and clinical features of the appearance of pain syndrome in the maxillofacial region in patients with chronic kidney disease is presented. The mechanisms of the effect of uremic intoxication on the oral mucosa and the peripheral nervous system are considered. Specific conditions such as uremic stomatitis, trigeminal neuropathy, and burning mouth syndrome have been identified. Special attention is paid to the manifestations of bone mineral disorders (CKD-MBD), including renal osteodystrophy of the jaws. The approach to pharmacological pain relief is systematized: a strict ban on the use of nonsteroidal anti-inflammatory drugs (NSAIDs) is justified and algorithms for the safe dosing of analgesics and adjuvants (gabapentinoids) are proposed, taking into account the reduced glomerular filtration rate and dialysis clearance. Clinical recommendations on dental treatment tactics, including hemostasis measures and timing of hemodialysis sessions to minimize the risks of complications, are also formulated.
- 7 August 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (7)
Ethical and clinical aspects of genetic analysis in neurodegenerative diseases
Objective. Too conduct a comprehensive analytical review of the limitations of traditional genetic methodologies compared with contemporary high-resolution technologies, such as single-cell and single-nucleus RNA sequencing (sc/snRNA-seq). It will explore in detail the mechanisms underlying the incomplete penetrance of pivotal risk genes, namely LRRK2 and GBA1, and systematically organize data on pathological alterations in specific target cell types, including microglia, astrocytes, oligodendrocytes, and selectively vulnerable neurons. Material and methods. The analysis presented in this paper is grounded in a review of contemporary transcriptomic, genomic, and clinical research. Emphasis is placed on integrating data from genome-wide association studies (GWAS) with single-cell expression atlases, as well as findings from functional studies conducted in model organisms and in cell cultures derived from mutation carriers. Results. The findings indicate that conventional sequencing techniques are inadequate for detecting cell-specific dysfunctions, particularly within rare cell populations. Technologies such as scRNA-seq have demonstrated that the LRRK2 and GBA1 genes exhibit significant expression levels in glial cells, where they are involved in critical processes including immune response modulation, lysosomal function, and cytoskeletal organization. Mutations in LRRK2 reprogram pro-inflammatory microglia and alter astrocyte morphology through hyperphosphorylation of ERM proteins. In contrast, GBA1 deficiency initiates a cascade of lysosomal stress that impacts not only neurons but also astrocytes and oligodendrocytes. The phenomenon of incomplete penetrance is examined, revealing penetrance rates ranging from 10% to 85% that vary by ethnic background and polygenic factors, thereby posing significant challenges for medical and genetic counseling. Conclusions. Neurodegeneration is a systemic process characterized by disruption of glial cell homeostasis, which acts as a pathogenic driver. The advancement of single-cell analytical techniques paves the way for the identification of new therapeutic targets to correct the dysfunction of specific cell populations. The phenomenon of incomplete penetrance necessitates a reevaluation of the strategies used to predict and apply polygenic risk assessments in clinical practice.
- 7 August 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (7)
Ethical and clinical aspects of genetic analysis in neurodegenerative diseases
Objective. Too conduct a comprehensive analytical review of the limitations of traditional genetic methodologies compared with contemporary high-resolution technologies, such as single-cell and single-nucleus RNA sequencing (sc/snRNA-seq). It will explore in detail the mechanisms underlying the incomplete penetrance of pivotal risk genes, namely LRRK2 and GBA1, and systematically organize data on pathological alterations in specific target cell types, including microglia, astrocytes, oligodendrocytes, and selectively vulnerable neurons. Material and methods. The analysis presented in this paper is grounded in a review of contemporary transcriptomic, genomic, and clinical research. Emphasis is placed on integrating data from genome-wide association studies (GWAS) with single-cell expression atlases, as well as findings from functional studies conducted in model organisms and in cell cultures derived from mutation carriers. Results. The findings indicate that conventional sequencing techniques are inadequate for detecting cell-specific dysfunctions, particularly within rare cell populations. Technologies such as scRNA-seq have demonstrated that the LRRK2 and GBA1 genes exhibit significant expression levels in glial cells, where they are involved in critical processes including immune response modulation, lysosomal function, and cytoskeletal organization. Mutations in LRRK2 reprogram pro-inflammatory microglia and alter astrocyte morphology through hyperphosphorylation of ERM proteins. In contrast, GBA1 deficiency initiates a cascade of lysosomal stress that impacts not only neurons but also astrocytes and oligodendrocytes. The phenomenon of incomplete penetrance is examined, revealing penetrance rates ranging from 10% to 85% that vary by ethnic background and polygenic factors, thereby posing significant challenges for medical and genetic counseling. Conclusions. Neurodegeneration is a systemic process characterized by disruption of glial cell homeostasis, which acts as a pathogenic driver. The advancement of single-cell analytical techniques paves the way for the identification of new therapeutic targets to correct the dysfunction of specific cell populations. The phenomenon of incomplete penetrance necessitates a reevaluation of the strategies used to predict and apply polygenic risk assessments in clinical practice.
- 1 July 2026
- Published by Springer Nature in Neuroscience and Behavioral Physiology
- Vol. 56 (6) , 952-960
Selective Neurodegeneration in Patients with Parkinson’s Disease
- 1 July 2026
- Published by Springer Nature in Neuroscience and Behavioral Physiology
- Vol. 56 (6) , 952-960
Selective Neurodegeneration in Patients with Parkinson’s Disease
- 26 June 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (6) , 23-28
Pain and cognitive impairment: from sensory indifference to neurodegenerative phenotype
Objective. To systematize and analyze modern scientific data on pain sensitivity in patients with cognitive impairment, focused on its potential value as a neurophysiological biomarker of neurodegeneration. Material and methods. A targeted review of peer-reviewed papers available in the PubMed, Scopus, Web of Science, and Google Scholar databases was conducted, mainly since 2015. The review includes original studies, systematic reviews, and meta-analyses on pain sensitivity in dementia, neurophysiological aspects of pain perception, and pathophysiological mechanisms linking chronic pain to neurodegenerative processes. Results. The review revealed a paradoxical dissociation between a decrease in complaints of pain and a persistent or enhanced neuronal response to pain stimuli in patients with dementia. Major mechanisms include prefrontal cortex dysfunction, impaired downward pain modulation, neuroinflammation, and glial activation. Clinically, they manifest as an increase in pain thresholds along with an increase in the affective component of pain, leading to underdiagnosis and inadequate therapy. Conclusion. The change in pain sensitivity in patients with cognitive impairment is not a quantitative reduction, but a qualitative dysregulation of pain perception. This phenomenon reflects the neurodegeneration severity and may serve as a promising biomarker for dementia. Longitudinal studies and the development of standardized assessment methods are required for its clinical validation.
- 26 June 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (6) , 23-28
Pain and cognitive impairment: from sensory indifference to neurodegenerative phenotype
Objective. To systematize and analyze modern scientific data on pain sensitivity in patients with cognitive impairment, focused on its potential value as a neurophysiological biomarker of neurodegeneration. Material and methods. A targeted review of peer-reviewed papers available in the PubMed, Scopus, Web of Science, and Google Scholar databases was conducted, mainly since 2015. The review includes original studies, systematic reviews, and meta-analyses on pain sensitivity in dementia, neurophysiological aspects of pain perception, and pathophysiological mechanisms linking chronic pain to neurodegenerative processes. Results. The review revealed a paradoxical dissociation between a decrease in complaints of pain and a persistent or enhanced neuronal response to pain stimuli in patients with dementia. Major mechanisms include prefrontal cortex dysfunction, impaired downward pain modulation, neuroinflammation, and glial activation. Clinically, they manifest as an increase in pain thresholds along with an increase in the affective component of pain, leading to underdiagnosis and inadequate therapy. Conclusion. The change in pain sensitivity in patients with cognitive impairment is not a quantitative reduction, but a qualitative dysregulation of pain perception. This phenomenon reflects the neurodegeneration severity and may serve as a promising biomarker for dementia. Longitudinal studies and the development of standardized assessment methods are required for its clinical validation.
- 5 June 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (5) , 14-20
Predictive epileptology: the emergence of a new paradigm for the management of epileptic seizures
Objective. To assess the current state and potential use of wearable devices with artificial intelligence (AI) for the prediction of epileptic seizures. Material and methods. Scientific papers published within the last five years were used for this review, except for fundamental publications. The literature was selected from scientific databases Scopus, PubMed, Google Scholar, and eLibrary. Results. The findings indicate that predicting epileptic seizures with AI-based wearable devices is technologically feasible. Contemporary algorithms, particularly personalized deep learning models, demonstrate predictive accuracy that surpasses random chance by analyzing data from multimodal sensors. Nevertheless, a substantial gap persists between the high accuracy observed in laboratory settings and the more moderate, though clinically meaningful, performance in real-world environments. For patients, these technologies offer significant benefits, including reduced chronic anxiety, enhanced safety, and improved autonomy. Major barriers to widespread adoption include elevated false alarm rates, challenges in predicting non-motor seizures, and considerable regulatory, ethical, and economic constraints. Conclusion. Wearable AI-based devices mark a fundamental shift in epilepsy management from reactive response to proactive risk management. While the technology has proven its great potential, it is not yet ready for mass clinical introduction due to existing technical and non-technical barriers. The future of this area lies in the development of integrated «closed-loop» systems that automatically trigger therapeutic interventions based on accurate prognoses. Ultimately, these innovations are not just technological advances, but powerful tools that can improve the quality of life for millions of people.
- 5 June 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (5) , 14-20
Predictive epileptology: the emergence of a new paradigm for the management of epileptic seizures
Objective. To assess the current state and potential use of wearable devices with artificial intelligence (AI) for the prediction of epileptic seizures. Material and methods. Scientific papers published within the last five years were used for this review, except for fundamental publications. The literature was selected from scientific databases Scopus, PubMed, Google Scholar, and eLibrary. Results. The findings indicate that predicting epileptic seizures with AI-based wearable devices is technologically feasible. Contemporary algorithms, particularly personalized deep learning models, demonstrate predictive accuracy that surpasses random chance by analyzing data from multimodal sensors. Nevertheless, a substantial gap persists between the high accuracy observed in laboratory settings and the more moderate, though clinically meaningful, performance in real-world environments. For patients, these technologies offer significant benefits, including reduced chronic anxiety, enhanced safety, and improved autonomy. Major barriers to widespread adoption include elevated false alarm rates, challenges in predicting non-motor seizures, and considerable regulatory, ethical, and economic constraints. Conclusion. Wearable AI-based devices mark a fundamental shift in epilepsy management from reactive response to proactive risk management. While the technology has proven its great potential, it is not yet ready for mass clinical introduction due to existing technical and non-technical barriers. The future of this area lies in the development of integrated «closed-loop» systems that automatically trigger therapeutic interventions based on accurate prognoses. Ultimately, these innovations are not just technological advances, but powerful tools that can improve the quality of life for millions of people.
- 1 June 2026
- Published by Springer Nature in Neuroscience and Behavioral Physiology
- Vol. 56 (5) , 781-787
Neurogenesis in Neurodegeneration: Multifactorial Regulation, Mechanisms of Impairment, and Therapeutic Strategies
- 1 June 2026
- Published by Springer Nature in Neuroscience and Behavioral Physiology
- Vol. 56 (5) , 781-787
Neurogenesis in Neurodegeneration: Multifactorial Regulation, Mechanisms of Impairment, and Therapeutic Strategies